Serve

from Wikipedia, the free encyclopedia
Serve

logo
legal form SAS
founding 1954
Seat Suresnes , FranceFranceFrance 
management Olivier Laureau ( President )
Number of employees 21,700 (2017)
sales 4.15 billion euros (2017)
Branch pharmacy
Website www.servier.de
www.servier.com

Les Laboratoires Servier is a French private pharmaceutical company founded in 1954 by the doctor and pharmacist Dr. Jacques Servier was founded. Servier is the second largest French pharmaceutical company and generated worldwide sales of around 4.15 billion euros in 2017. The company's headquarters are located near Paris ( Suresnes ), France . The company employs around 21,700 people in around 150 countries. Around 25 percent of pharmaceutical sales are invested in research and development. The German sales subsidiary has existed since 1996 - a German subsidiary for clinical research has existed since 1985.

history

In 1954 Servier was founded by the doctor and pharmacist Dr. Jacques Servier founded as a research laboratory with nine people. In 2018 Servier employed 21,700 people in around 150 countries.

Since the death of the company's founder Jacques Servier in 2014, the company has been transformed into a foundation and is managed by a board of trustees headed by Olivier Laureau.

Servier consists of two business units in Germany:

  • Servier Deutschland GmbH, Munich (founded 1996): u. a. Administration, medicine, health policy / market access, marketing and sales.
  • Servier Research and Pharma Development GmbH, Munich (founded 1985): Clinical studies for all DACH countries and, since 2017, also for the Benelux countries.

Oliver Kirst is the managing director of Servier Deutschland GmbH. The managing director of Servier Research and Pharma Development GmbH is Dr. Arne Sakrauski.

Medication

In Germany, drugs for the treatment of cardiovascular diseases , oncology and depression are marketed in particular .

Deprexis24 is an interactive, modular online psychotherapy program for the treatment of mild to moderate depression . The program simulates an individual, dynamic dialogue with the patient and flexibly links ten subject areas, mainly from the field of cognitive behavioral therapy .

Research and development / cooperation

The main areas in Servier's research are cardiovascular diseases, neuropsychiatry , oncology , diabetes and autoimmune diseases . In addition, Servier is pushing the research, development and sales of patient-oriented digital applications "beyond the pill". From Munich, Servier is responsible for clinical studies for the so-called DACH countries (Germany, Austria, Switzerland) and, since 2017, for the Benelux countries. Servier was able to provide some drugs as “first-in-class / best-in-class”. These efforts were recognized in 2009 with the Galenus von Pergamon Prize (Prix Galien) , which Servier received for Procoralan .

Servier maintains various partnerships with various companies:

  • At the end of August 2018, Servier took over Shire's international oncology business .
  • Since June 2018, Servier and the Dutch company Galapagos NV have been researching a new therapy option for the treatment of knee osteoarthritis .
  • A new research approach for the treatment of autism in children is being investigated together with the cooperation partner Neurochlore .
  • Servier entered into a sales cooperation with Novartis in Germany in October 2017. The core of the agreement is the Germany-wide co-promotion of Sacubitril / Valsartan (trade name : Entresto ) for the treatment of chronic heart failure with a reduced ejection fraction .
  • Since May 2017 there has been an expansion of the cooperation between Servier and CTI BioPharma for the marketing of Pixuvri in Germany as well.
  • In the area of multiple sclerosis , the Swiss biotechnology company GeNeuro is investigating whether a certain type of retrovirus could trigger multiple sclerosis and how this virus-induced course of the disease could be reduced or even stopped with medication.
  • Servier entered into a sales cooperation with Boehringer Ingelheim in Germany in February 2017. The core of the agreement is the Germany-wide joint marketing (co-promotion) of Pradaxa ( dabigatran ) and Praxbind ( idarucizumab , i.e. a monoclonal antibody ) for certain cardiovascular diseases.
  • At the beginning of 2017 there was a collaboration with the American biotechnology company Pieris Pharmaceuticals in the area of "dual PD-1 checkpoint inhibition" to fight cancer cells through the body's own immune system. A total of up to five therapeutic programs are jointly developed and, if successful, the distribution rights are divided geographically.
  • In September 2016, Amgen and Servier announced an expansion of their cooperation in the field of cardiovascular diseases.
  • A research collaboration in the field of cell-based cancer immunotherapeutics (UCART) has existed with Pfizer since November 2015.
  • Since November 2014 there has been a cooperation in the field of type II diabetes with the American biotechnology company Intarcia Therapeutics . The American approval for this was submitted by Intarcia in November 2016.

Social Responsibility / Serving Science Awards

Servier shows social responsibility in numerous areas (including the Paul Nikolai Ehlers Foundation, German Care Day, health initiative with handball Bundesliga club Füchse Berlin, Life Views Foundation: early detection of colon cancer). Servier is also committed to science and awards the following science prizes:

  • Franz Loogen Prize

The award named after Franz Loogen is awarded annually to scientists who saw, established and / or pursued a new development in the field of cardiology at an early stage and thus opened up a new field of knowledge.

  • Rudi Busse Young Investigator Award

The prize named after Rudi Busse is awarded to young experimental scientists up to 35 years of age.

  • Hermann Rein Prize

The prize, named after Hermann Rein , is awarded to scientists for outstanding achievements in the field of experimental or clinical research in microcirculation and vascular biology.

Galen of Pergamon Prize (Prix Galien)

In 2009 Servier received the Galenus von Pergamon Prize (Prix Galien) in the Primary Care category for Procoralan .

Criticism of the "Mediator" preparation

The appetite suppressant "Mediator" was sold by Servier until the preparation was banned across Europe in 2009. The product is held responsible for the death of at least 500 people in France. Several thousand people had to go to inpatient treatment because the drug is said to have caused cardiovascular damage. The judicial review of the effects of the product is to continue until April 2020.

See also

Web links

Individual evidence

  1. ↑ a b c Members of the Foundation Council , Company WebSite Servier, accessed September 5, 2018
  2. ↑ a b c d Key Figures , WebSite Servier, accessed on September 5, 2018
  3. ↑ History WebSite Servier, accessed June 8, 2017
  4. ↑ Servier in Germany , WebSite Servier Germany, accessed on September 10, 2018
  5. ↑ Implicor specialist information , accessed on June 8, 2017
  6. ↑ Lonsurf specialist information , accessed on June 8, 2017
  7. ↑ G-BA confirms additional benefit for colon cancer drug , PM Servier dated February 6, 2017, accessed on June 8, 2017
  8. ↑ Phase III study to evaluate the efficacy and safety of Lonsurf (trifluridine / tipiracil) in patients with metastatic gastric cancer who are resistant to standard therapies (the TAGS study), meets primary endpoint , Servier Media Relations, May 9, 2018, accessed on September 7, 2018
  9. ↑ a b c Servier finalizes acquisition of Shire's oncology branch , PM Servier, August 31, 2018, accessed September 5, 2018
  10. ↑ Specialist information Oncaspar , accessed on September 6, 2018
  11. ↑ Summary of Product Characteristics , EMA, accessed September 6, 2018
  12. ↑ Summary of the EPAR for the public , European Medicines Agency (EMA), accessed on June 8, 2017
  13. ↑ Specialist information Preterax , accessed on June 8, 2017
  14. ↑ technical information BiPreterax , accessed on 8 June 2017
  15. ^ Technical information Procoralan , accessed on June 8, 2017
  16. ^ Specialist information Protelos , accessed on June 8, 2017
  17. ↑ Protelos®: End of production from August 2017 , PM Servier from April 20, 2017, accessed on June 8, 2017
  18. ↑ Specialist information Triveram , accessed on June 8, 2017
  19. ^ Technical information Valdoxan , accessed on June 8, 2017
  20. ↑ Specialist information Viacoram , accessed on June 8, 2017
  21. ↑ Deprexis24 , WebSite of Servier Germany, accessed on June 8, 2017
  22. ↑ Online therapy program deprexis®24 for those insured with the DAK also in 2017 , PM Servier dated April 7, 2017, accessed on June 8, 2017
  23. ↑ Management of Depression in the General Practitioner, PM Servier, April 30, 2017, accessed June 8, 2017
  24. ↑ SERVIER Research Centers , WebSite Servier Germany, accessed on September 7, 2018
  25. ↑ What is it about “Beyond the Pill”? , Coliquio Insights September 18, 2017, accessed September 7, 2018
  26. ↑ a b Galenus von Pergamon Prize , Ärzte Zeitung of October 19, 2009, accessed on June 8, 2017
  27. ↑ Servier Completes Acquisition of Shire Oncologics , Ärztezeitung September 3, 2018, accessed September 5, 2018
  28. ↑ Shire sells cancer drugs to Servier for $ 2.4 billion as Takeda circles , Reuters, April 16, 2018, accessed September 5, 2018
  29. ↑ Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086 / GLPG1972 in osteoarthritis , PM Servier, June 27, 2018, accessed on September 7, 2018
  30. ↑ Servier, Galapagos kick off therapeutic candidate phase 2 trial for knee osteoarthritis patients , pharmaceutical daily news of June 27, 2018, accessed on September 7, 2018
  31. ↑ Servier and Neurochlore join forces to treat autism in children , Servier PM, March 14, 2018, accessed September 7, 2018
  32. ^ Servier in co-distribution for Sacubitril / Valsartan , Ärztezeitung from October 18, 2017, accessed on September 7, 2018
  33. ↑ Servier supplements oncology portfolio by expanding cooperation with CTI BioPharma ( Memento of the original from May 22, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , PM Servier on May 3, 2017, accessed June 8, 2017 @1@ 2Template: Webachiv / IABot / www.servier.de
  34. ↑ Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI® , PM CTI BioPharma from April 25, 2017, accessed on June 8, 2017
  35. ↑ GeNeuro Reports 2016 Full-Year Results and Provides Corporate Update , PR GeNeuro of April 27, 2017, accessed on June 8, 2017
  36. ↑ Sales cooperation between Servier and Boehringer Ingelheim in Germany , PM Servier from February 20, 2017, accessed on June 8, 2017
  37. ↑ Boehringer Ingelheim strengthens the distribution of Pradaxa® and Praxbind® in Germany through cooperation with Servier , PM Boehringer Ingelheim from February 20, 2017, accessed on June 8, 2017
  38. ↑ Pieris, Servier partner on immuno-oncology , PM CenterWatch, January 6, 2017, accessed June 8, 2017
  39. ↑ Amgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure , PM Amgen, September 1, 2016, accessed June 8, 2017
  40. ↑ Pfizer, Servier to develop Cellectis' CAR-T cell therapy pharmatimes, November 20, 2015, accessed on September 7, 2018
  41. ↑ Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT annual meeting , PM Servier, March 8, 2018, accessed September 7, 2018
  42. ↑ Intarcia and Servier Sign Ex-US Partnership for ITCA 650 in Diabetes , PM Intarcia, November 12, 2014, accessed June 12, 2017
  43. ↑ Intarcia Submits New Drug Application (NDA) to FDA for US Marketing Approval of ITCA 650 in Type 2 Diabetes , PM Intarcia, November 2016, accessed June 12, 2017
  44. ↑ a b c SERVIER is committed to science , WebSite Servier Germany, accessed on June 8, 2017
  45. ↑ Trial of Deadly Slimming Pills , faz.net, accessed September 23, 2019

Coordinates: 48 ° 52 '25 "  N , 2 ° 13' 36.5"  E